Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1900-1902

  Trandafir, L ^a   Ruffie P ^a   Borel, C ^a   Monnet, I ^c   Soulie P ^b   Adams, D ^d   Cvitkovic, E ^b   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Cisplatin interferon; Malignant mesothelioma

Indexed keywords

ALPHA INTERFERON; CISPLATIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0031423734     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00263-3     Document Type: Article

References (7)

1. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemo-immunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alpha 2.2, . J Clin Oncol 1996, 14(3), 878-885.
2. Amato R, Meyers C, Ellerhorst J, et al. A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 1995, 6, 911-914.
3. Gosland MP, Goodin S, Yokel RA, Smith M, John WJ. A phase I trial of 5-day continuous infusion cisplatin and interferon a. Cancer Chemother Pharmacol 1995, 37, 39-46.
4. Dhingra K, Talpaz M, Dhingra HM, et al. A phase I trial of recombinant alpha-2a interferon (Roferon A) with weekly cis-platinum. Invest New Drugs 1991, 9, 37-39.
5. Bowman A, Fergusson RJ, Allan SG, et al. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 1990, 1, 351-353.
6. Richner J, Joss RA, Goldhirsch A, Brunner KW. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992, 28A, 1044-1047.
7. Ardizzoni A, Salvato F, Rosso R, et al. Combination of chemotherapy and recombinant alpha-interferon in advanced nonsmall cell lung cancer. Cancer 1993, 72, 2929-2935.